NSTK · 01.2026Independent supplement reference
NutriStack
Edition 1.0Updated July 13, 2026

Zoledronic Acid

Prescription ·Exploratory record · not publication-reviewed ·Updated July 13, 2026

Zoledronic acid is the most potent bisphosphonate available, administered as an annual IV infusion for osteoporosis (Reclast) or more frequently for hypercalcemia of malignancy and bone metastases (Zometa). The HORIZON-PFT trial demonstrated significant fracture reduction with once-yearly dosing. Its IV administration eliminates GI side effects and adherence concerns of oral bisphosphonates.

Evidence tier
Strong
Indexed sources
10 2013–2024
Interactions
0
Depletes
2 nutrients
Read the sources → Compare profiles
Publication status

Exploratory record, not a reviewed medical publication.

See the editorial and medical-review policies for the publication gate.

This generated database record has not completed a claim-level review by a qualified human medical reviewer. Bibliography links and evidence labels are not approval. The page remains available for reference and is excluded from search indexing.

In short

What the research says.

A quick, data-only summary. The full evidence, dosing, and sources are below.

Zoledronic acid is the most potent bisphosphonate available, administered as an annual IV infusion for osteoporosis (Reclast) or more frequently for hypercalcemia of malignancy and bone metastases (Zometa). NutriStack rates the supporting evidence as strong. Common adult dosing is Osteoporosis: 5 mg IV once yearly; Paget's: 5 mg single IV dose; Hypercalcemia of malignancy: 4 mg IV (as prescribed by your physician), though a prescriber sets the actual dose. With long-term use it can deplete calcium, phosphorus. This profile indexes 10 sources.

What it's good for
  • Once-yearly IV infusion ensures 100% adherence6
  • Reduces vertebral fractures by 70% (HORIZON-PFT)7,6
  • Reduces hip fractures by 41%7
  • Reduces all-cause mortality in hip fracture patients (HORIZON-RFT)7,3
  • No GI side effects of oral bisphosphonates8,10
What to watch for
  • Acute phase reaction (fever, myalgia, headache, arthralgia) within 1–3 days of infusion
  • Hypocalcemia
  • Renal impairment (ensure adequate hydration, infuse over ≥15 minutes)
  • Hypocalcemia (must correct before infusion)
  • Severe renal impairment (CrCl <35 mL/min for osteoporosis indication)

The bottom line

Evidence rating strong. Most-documented uses: once-yearly iv infusion ensures 100% adherence, reduces vertebral fractures by 70% (horizon-pft), reduces hip fractures by 41%. 10 sources indexed (2013–2024), with 0 interaction records on file.

The science

How it works, mechanistically.

Core mechanism

The most potent inhibitor of farnesyl pyrophosphate synthase among bisphosphonates. After IV infusion, rapidly binds to hydroxyapatite at bone surfaces. During osteoclast-mediated bone resorption, zoledronic acid is internalized and disrupts the mevalonate pathway, preventing prenylation of small GTPases essential for osteoclast function and survival. This potently inhibits bone resorption and reduces bone turnover markers.

Class
Bisphosphonate
Dosing

Dosing & protocol.

Common range
Osteoporosis: 5 mg IV once yearly; Paget's: 5 mg single IV dose; Hypercalcemia of malignancy: 4 mg IV (as prescribed by your physician)
Recommended form
Intravenous infusion over at least 15 minutes

Given as IV infusion. Patient should be well hydrated before infusion. Ensure adequate calcium and vitamin D supplementation.

Depletions

What it depletes.

Nutrients this medication can lower over time, and what to replace.

Calcium

Significant

Potent IV bisphosphonate therapy can acutely suppress bone resorption and lower serum calcium, especially with low vitamin D status or kidney impairment.

Replace CalciumMonitor Serum calcium + 25-OH vitamin DOnset Usually within days to weeks after infusion

Phosphorus

Moderate

Zoledronic acid can cause renal and bone-mineral shifts that produce clinically important hypophosphatemia after infusion in susceptible patients.

Monitor Serum phosphorusOnset Usually within days to weeks after infusion

Full Zoledronic Acid depletion and interaction guide →

Safety

Full safety detail.

Side effects

  • Acute phase reaction (fever, myalgia, headache, arthralgia) within 1–3 days of infusion
  • Hypocalcemia
  • Renal impairment (ensure adequate hydration, infuse over ≥15 minutes)
  • Osteonecrosis of the jaw (rare, more common in oncology dosing)
  • Atypical femoral fractures (rare, with prolonged use)
  • Ocular inflammation (uveitis, scleritis; rare)
  • Bone, joint, and muscle pain

Contraindications

  • Hypocalcemia (must correct before infusion)
  • Severe renal impairment (CrCl <35 mL/min for osteoporosis indication)
  • Known hypersensitivity to zoledronic acid or other bisphosphonates1,2
  • Pregnancy and breastfeeding
Sources

Sources, by evidence tier.

Numbered references. Citations throughout the page link here.

Meta-analyses & systematic reviews

5

Reference material

5
FAQ

Common questions.

Quick answers about Zoledronic Acid, drawn from the data on this page.

What is Zoledronic Acid?

Zoledronic acid is the most potent bisphosphonate available, administered as an annual IV infusion for osteoporosis (Reclast) or more frequently for hypercalcemia of malignancy and bone metastases (Zometa). The HORIZON-PFT trial demonstrated significant fracture reduction with once-yearly dosing. Its IV administration eliminates GI side effects and adherence concerns of oral bisphosphonates.

What is Zoledronic Acid used for?

Commonly cited benefits of Zoledronic Acid include: Once-yearly IV infusion ensures 100% adherence; Reduces vertebral fractures by 70% (HORIZON-PFT); Reduces hip fractures by 41%; Reduces all-cause mortality in hip fracture patients (HORIZON-RFT); No GI side effects of oral bisphosphonates. NutriStack rates the overall evidence as strong.

What is a typical dose of Zoledronic Acid?

A typical adult dose of Zoledronic Acid is Osteoporosis: 5 mg IV once yearly; Paget's: 5 mg single IV dose; Hypercalcemia of malignancy: 4 mg IV (as prescribed by your physician). The commonly recommended form is Intravenous infusion over at least 15 minutes. These are general ranges, not personalized advice; confirm the right dose with a clinician.

What are the side effects of Zoledronic Acid?

Reported side effects include acute phase reaction (fever, myalgia, headache, arthralgia) within 1–3 days of infusion, hypocalcemia, renal impairment (ensure adequate hydration, infuse over ≥15 minutes), osteonecrosis of the jaw (rare, more common in oncology dosing), atypical femoral fractures (rare, with prolonged use), ocular inflammation (uveitis, scleritis; rare). This is educational information; check with a healthcare professional before use.

How strong is the evidence for Zoledronic Acid?

NutriStack rates this as Strong, meaning multiple high-quality meta-analyses or systematic reviews converge on the same finding. Full tier criteria are at https://nutristackapp.com/methodology/evidence-tiers.

Use this with your stack

Zoledronic Acid in NutriStack.

Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.

Download on the App Store → Read the methodology

NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.